USP and Russia Make Headway on Improving Drug Quality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP and Russia Make Headway on Improving Drug Quality


ePT--the Electronic Newsletter of Pharmaceutical Technology

In April 2009, the US Pharmacopeial Convention (USP) and the Russian Federation’s regulatory agency, Roszdravnadzor, signed a memorandum of understanding to work toward protecting and improving the quality of medicines worldwide. Last week, USP and the Ukraine Scientific Pharmacopoeial Centre for the Quality of Medicines agreed to share standards for the quality, purity, strength, and identity of medicines. The Ukrainian center will have a five-year, renewable right to include written standards (as written or modified) from the US Pharmacopeia–National Formulary (USP–NF) in its own pharmacopoeia and companion journal, Pharmacom.

“This agreement is a milestone in helping to promote public health internationally. The scientific exchange represented by the agreement with the Centre will benefit not only the citizens of the Ukraine, but also Ukrainian manufacturers wishing to export to other countries,” said USP chief executive officer Roger Williams in a press release. “USP will benefit from the experience of the Centre’s scientists, which in turn contributes to the strength of the standards published in the USP–NF.”

The Ukrainian center also will explore opportunities to use USP’s accompanying reference standards to help evaluate drug quality and identity, according to the release.

Also last week, USP announced that it had completed a series of eight drug quality courses at Moscow’s Scientific Center for Expertise of Medical Products as part of ongoing collaborative efforts.

The original MOU from April 2009 called for USP and Roszdravnadzor to increase working relationships by exchanging scientific staff, facilitating the exchange of information, developing and using reference materials, and establishing third-party certification programs to allow for the review, testing, and auditing of drug manufacturers in the two countries.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here